An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer

British Journal of Cancer

Volumn 114, Issue 1, 2016, Pages 37-43

  O'Donnell, Charlotte ^a   Mahmoud, Amr ^a   Keane, Jonathan ^a,b   Murphy, Carola ^c   White, Declan ^a,b   Carey, Sinead ^d   O'Riordain, Micheal ^b,e   Bennett, Michael W ^d   Brint, Elizabeth ^a,b   Houston, Aileen ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c UNIVERSITY COLLEGE CORK   (Ireland)

^d Department of Medicine National University of Ireland Cork   (Ireland)

^e MERCY UNIVERSITY HOSPITAL   (Ireland)

Author keywords

colon cancer; IL 33; inflammation; ST2

Indexed keywords

CYTOKINE RECEPTOR; INTERLEUKIN 33; INTERLEUKIN 33 RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; SHORT HAIRPIN RNA; ST2L PROTEIN; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; IL33 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRADING; CELL INFILTRATION; COLON CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; CELL PROLIFERATION; COLONIC NEOPLASMS; PATHOLOGY; PHYSIOLOGY; TUMOR INVASION;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; COLONIC NEOPLASMS; FEMALE; HUMANS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; INTERLEUKIN-33; MACROPHAGES; MICE; MICE, INBRED BALB C; NEOPLASM GRADING; NEOPLASM INVASIVENESS; RECEPTORS, CELL SURFACE;

EID: 84954393953     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.433     Document Type: Article

References (23)

1. Barrera L, Montes-Servin E, Barrera A, Ramirez-Tirado LA, Salinas-Parra F, Banales-Mendez JL, Sandoval-Rios M, Arrieta O. (2015). Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis. Ann Oncol. 26(2): 428-435.
2. Bergis D, Kassis V, Ranglack A, Koeberle V, Piiper A, Kronenberger B, Zeuzem S, Waidmann O, Radeke HH. (2013). High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma. Transl Oncol. 6(3): 311-318.
3. Chen XJ, Huang YD, Li N, Chen M, Liu F, Pu D, Zhou TY. (2014). Correlations between serum IL33 and tumor development: a meta-Analysis. Asian Pac J Cancer Prev. 15(8): 3503-3505.
4. Cui G, Qi H, Gundersen MD, Yang H, Christiansen I, Sorbye SW, Goll R, Florholmen J. (2015). Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer. Cancer Immunol Immunother. 64(2): 181-190.
5. Edin S, Wikberg ML, Oldenborg PA, Palmqvist R. (2013). Macrophages: good guys in colorectal cancer. Oncoimmunology. 2(2): e23038.
6. Fang KM, Yang CS, Lin TC, Chan TC, Tzeng SF. (2014). Induced interleukin-33 expression enhances the tumorigenic activity of rat glioma cells. Neuro Oncol. 16(4): 552-566.
7. Fernandes P, MacSharry J, Darby T, Fanning A, Shanahan F, Houston A, Brint E. (2015). Differential expression of key regulators of Toll-like Receptors in Ulcerative Colitis and Crohn's disease: A role for Tollip and PPARgamma? Clin Exp Immunol; e-pub ahead of print 14 October 2015; doi:10.1111/cei.12732.
8. Gao X, Wang X, Yang Q, Zhao X, Wen W, Li G, Lu J, Qin W, Qi Y, Xie F, Jiang J, Wu C, Zhang X, Chen X, Turnquist H, Zhu Y, Lu B. (2015). Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8- T and NK cells. J Immunol. 194(1): 438-445.
9. Garlanda C, Dinarello CA, Mantovani A. (2013). The interleukin-1 family: back to the future. Immunity. 39(6): 1003-1018.
10. Gillibert-Duplantier J, Duthey B, Sisirak V, Salaun D, Gargi T, Tredan O, Finetti P, Bertucci F, Birnbaum D, Bendriss-Vermare N, Badache A. (2012). Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis. Oncogene. 31(30): 3516-3524.
11. Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN, Lukic ML. (2014). Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer. 134(7): 1669-1682.
12. Liu X, Zhu L, Lu X, Bian H, Wu X, Yang W, Qin Q. (2014). IL-33/ST2 pathway contributes to metastasis of human colorectal cancer. Biochem Biophys Res Commun. 453(3): 486-492.
13. Lopetuso LR, Scaldaferri F, Pizarro TT. (2012). Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis. Fibrogenesis Tissue Repair. 5(1): 18.
14. Lu J, Kang J, Zhang C, Zhang X. (2015). The role of IL-33/ST2L signals in the immune cells. Immunol Lett. 164(1): 11-17.
15. Masamune A, Watanabe T, Kikuta K, Satoh K, Kanno A, Shimosegawa T. (2010). Nuclear expression of interleukin-33 in pancreatic stellate cells. Am J Physiol Gastrointest Liver Physiol. 299(4): G821-G832.
16. Maywald RL, Doerner SK, Pastorelli L, De Salvo C, Benton SM, Dawson EP, Lanza DG, Berger NA, Markowitz SD, Lenz HJ, Nadeau JH, Pizarro TT, Heaney JD. (2015). IL-33 activates tumor stroma to promote intestinal polyposis. Proc Natl Acad Sci USA. 112(19): E2487-E2496.
17. Musolino C, Allegra A, Profita M, Alonci A, Saitta S, Russo S, Bonanno A, Innao V, Gangemi S. (2013). Reduced IL-33 plasma levels in multiple myeloma patients are associated with more advanced stage of disease. Br J Haematol. 160(5): 709-710.
18. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H. (1998). CD8 T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58(16): 3491-3494.
19. Pastorelli L, Garg RR, Hoang SB, Spina L, Mattioli B, Scarpa M, Fiocchi C, Vecchi M, Pizarro TT. (2010). Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci USA. 107(17): 8017-8022.
20. Sedhom MA, Pichery M, Murdoch JR, Foligne B, Ortega N, Normand S, Mertz K, Sanmugalingam D, Brault L, Grandjean T, Lefrancais E, Fallon PG, Quesniaux V, Peyrin-Biroulet L, Cathomas G, Junt T, Chamaillard M, Girard JP, Ryffel B. (2013). Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut. 62(12): 1714-1723.
21. Sun P, Ben Q, Tu S, Dong W, Qi X, Wu Y. (2011). Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci. 56(12): 3596-3601.
22. Yang Q, Li G, Zhu Y, Liu L, Chen E, Turnquist H, Zhang X, Finn OJ, Chen X, Lu B. (2011). IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8 T cells. Eur J Immunol. 41(11): 3351-3360.
23. Zhang P, Liu XK, Chu Z, Ye JC, Li KL, Zhuang WL, Yang DJ, Jiang YF. (2012). Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications. J Int Med Res. 40(5): 1654-1661.